← Eichor
Condition: Polymyositis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Polymyositis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammato
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06599411Optimizing Treatment on Idiopathic Inflammatory Myopathies
Phase N/A · 1 location(s) · University of Sao Paulo · NCT03092180Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis
Phase 2/Phase 3 · 2 location(s) · Restem, LLC. · NCT07160205Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Phase 1 · 77 location(s) · Chugai Pharmaceutical · NCT06371417Natural History of Inflammatory Muscle Diseases
Phase N/A · 1 location(s) · National Institute of Arthritis and Musculoskeletal and Skin · NCT05738824Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06569472A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants Wit
Phase 1 · 37 location(s) · AstraZeneca · NCT06916806Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
Phase 2 · 1 location(s) · The Cleveland Clinic · NCT06857240A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathie
Phase 3 · 146 location(s) · Pfizer · NCT05895786BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy
Phase 1 · 1 location(s) · iCell Gene Therapeutics · NCT07715136Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
NA · 1 location(s) · Oslo University Hospital · NCT06732674Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositi
Phase N/A · 1 location(s) · National Institute of Arthritis and Musculoskeletal and Skin · NCT00059748A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Disease
Phase 1 · 28 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07115745A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With
Phase 1 · 14 location(s) · Allogene Therapeutics · NCT07085104Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
Phase 1 · 2 location(s) · Stanford University · NCT06298019Rheumatology Patient Registry and Biorepository
Phase N/A · 1 location(s) · Yale University · NCT04402086Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune D
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07558850Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06056921Severity Factors of Dermatomyositis in the Caribbean Population - DM-ANTILLES
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire de la Guadeloupe · NCT07265999Rheumatology Diet Study
Phase N/A · 1 location(s) · University of Central Florida · NCT06339957Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
Phase N/A · 9 location(s) · Peking Union Medical College Hospital · NCT06417502Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
Phase N/A · 1 location(s) · University of Pennsylvania · NCT02945345A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Phase 3 · 24 location(s) · Pfizer · NCT06698796Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
Phase N/A · 1 location(s) · Central Hospital, Nancy, France · NCT06004817Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07184450Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Phase 1/Phase 2 · 3 location(s) · Cartesian Therapeutics · NCT07089121Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06685042Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis
Phase N/A · 1 location(s) · CHU de Reims · NCT06462768A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Phase N/A · 1 location(s) · Kyverna Therapeutics · NCT07403188RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic I
Phase 2/Phase 3 · 35 location(s) · Cabaletta Bio · NCT06154252
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.